Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

482
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
482
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.6K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.6K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

755
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
755
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

267
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
267
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

4.4K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.4K
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

506
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
506

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Potential impact on cholesterol goal achievement and predicted cardiovascular risk by the addition of ezetimibe and bempedoic acid on top of statins: a simulation from the SANTORINI study.

American journal of preventive cardiology·2026
Same author

Lipid-lowering therapy after finding high Lp(a)-adding ezetimibe or intensifying statin treatment?

Journal of clinical lipidology·2026
Same author

Genetic determinants of childhood blood pressure and heart rate in relation to adult health outcomes: the consortium of childhood blood pressure.

European heart journal·2026
Same author

Brain magnetic resonance imaging biomarkers for future frailty; sub-study of FINGER trial.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Lipoprotein(a) levels in Finnish adults: distribution and associations with other cardiovascular risk factors and their awareness and control.

Lipids in health and disease·2026
Same author

Mechanistic explanation for the different statin response according to APOE genotypes.

British journal of clinical pharmacology·2026

相关实验视频

Updated: Feb 25, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.1K

75岁以上的老年人单独使用ezetimibe作为主要预防措施,以减少心血管事件.

Alpo Vuorio1,2, Petri T Kovanen3, Timo Strandberg4,5

  • 1Mehiläinen, Aviapolis Health Center, Vantaa, Finland.

Annals of medicine
|February 24, 2026
PubMed
概括
此摘要是机器生成的。

EWTOPIA 75研究表明,埃泽胺可减少在没有先前心脏病的老年人中发生动脉样硬化心血管疾病 (ASCVD) 的事件. 这种胆固醇吸收抑制剂可能由于与年龄相关的变化和有利的副作用概况而带来好处.

关键词:
这是一个ASCVD.吸收方式 吸收方式在 NPC1L1 基因中.胆固醇 胆固醇 胆固醇 是一种埃塞蒂米贝贝是什么意思这是一个古老的古老的古老的古老.

更多相关视频

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.8K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K

相关实验视频

Last Updated: Feb 25, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.1K
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.8K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K

科学领域:

  • 心脏病学 心脏病学
  • 老年病的医生 老年病的医生
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 动脉样性心血管疾病 (ASCVD) 仍然是导致发病和死亡的主要原因,特别是在老年人群中.
  • 胆固醇管理至关重要,但他类药物治疗可能不适合或不足于所有人,特别是老年人.
  • 在EWTOPIA 75研究中,研究了ezetimibe在75岁及以上的75岁及以上个体的ASCVD初级预防中的有效性.

研究的目的:

  • 为了评估以泽提单一治疗在减少ASCVD事件的有效性,在没有冠状动脉疾病史的老年人中.
  • 探索在这个特定的人口群体中为ezetimibe带来好处的潜在机制.
  • 为了为老年人失脂症管理的临床指南提供信息.

主要方法:

  • EWTOPIA 75研究涉及75岁或以上的参与者,没有确定的ASCVD.
  • 埃泽提米布作为单一疗法用于评估其对ASCVD事件风险的影响.
  • 研究设计侧重于初级预防的结果.

主要成果:

  • 在目标人群中,以泽提米布治疗证明了ASCVD事件的风险降低.
  • 观察到的好处可能与随着年龄增长的胆固醇吸收效率增加以及ezetimibe对非高密度脂蛋白胆固醇 (非HDL-C) 的作用有关.
  • 埃泽提米布可以减缓或稳定动脉样硬化过程,即使没有临床ASCVD.

结论:

  • 在75岁及以上没有先前冠状动脉疾病的个体中,埃泽蒂米布单一治疗有效降低ASCVD风险.
  • 与年龄相关的胆固醇吸收增加可能会提高ezetimibe在这个人群中的疗效.
  • 埃泽提米布的良好的安全性概况和更好的遵守潜力值得在老年人初级ASCVD预防中加以考虑.